Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Regenxbio (RGNX) over the last 10 years, with Q3 2025 value amounting to -$1.2.

  • Regenxbio's EPS (Weighted Average and Diluted) fell 256.41% to -$1.2 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year increase of 3107.57%. This contributed to the annual value of -$4.59 for FY2024, which is 2386.48% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's EPS (Weighted Average and Diluted) is -$1.2, which was down 256.41% from -$1.38 recorded in Q2 2025.
  • Regenxbio's EPS (Weighted Average and Diluted)'s 5-year high stood at $6.7 during Q4 2021, with a 5-year trough of -$1786.6 in Q1 2022.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$263.05, with a median of -$1.39 in 2022.
  • Data for Regenxbio's EPS (Weighted Average and Diluted) shows a peak YoY increase of 63981.95% (in 2021) and a maximum YoY decrease of 14889920.12% (in 2021) over the last 5 years.
  • Over the past 5 years, Regenxbio's EPS (Weighted Average and Diluted) (Quarter) stood at $6.7 in 2021, then crashed by 120.76% to -$1.39 in 2022, then fell by 3.7% to -$1.44 in 2023, then increased by 28.16% to -$1.04 in 2024, then fell by 15.88% to -$1.2 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$1.2 in Q3 2025, compared to -$1.38 in Q2 2025 and $0.12 in Q1 2025.